Safety of anacetrapib and moxifloxacin in healthy young subjects

Trial Profile

Safety of anacetrapib and moxifloxacin in healthy young subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 03 Dec 2015

At a glance

  • Drugs Anacetrapib (Primary) ; Moxifloxacin
  • Indications Atherosclerosis; Hypercholesterolaemia; Hyperlipidaemia; Hyperlipoproteinaemia type IIa
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 03 Dec 2015 New trial record
    • 23 Oct 2015 Results published in the Vaccine
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top